Innovation in healthcare provision and international trade expansions secures BioClad with a 2017 Queen’s Award.
BioClad is to receive the Queen’s Award in the category of International Trade, which has been officially announced on 21st April 2017 to celebrate the Queen’s birthday.
The Queen’s Award for Enterprise celebrates outstanding achievement by UK businesses in the categories of innovation, international trade, sustainable development and promoting opportunity through social mobility.
BioClad, which launched in 2008, now employs 20 people and has marked a 2000 per cent growth in exporting since broadening its horizons into international trade in 2011. Markets include Australia, Canada, India, Saudi Arabia, UAE and Mexico. BioClad has recently opened an Australian subsidiary in Perth and is poised to enter European markets.
BioClad Director Lindsay McKenzie said: “To be able to display the prestigious Queen’s Award emblem alongside our brand is a real honour. It acts as a stamp of approval which will be recognised not only by UK customers but by our trade partners across the world who appreciate the quality British businesses uphold.”
BioClad is the world’s number one in revolutionising antimicrobial hygienic spaces in healthcare, pharmaceutical, education, retail, restaurant and leisure sectors.
Our award-winning products such as antimicrobial wall cladding, hygienic wall cladding, wall protection, door protection, safety flooring and IPS Units are impregnated with BioCote silver-ion technology which kills microbes by 99.9% and is proven effective in protecting against E.Coli, MRSA and Influenza.
UK commissions include the biggest contract in the sector, for Hinkley Point C Nuclear Power Station. Alongside high-profile contracts in the leisure industry and a vast portfolio of high street retail and restaurant-chain expansions, BioClad has been working tirelessly with hospitals and health centres to radicalise care for patients.
BioClad antimicrobial products have been specified in large-scale projects including a £63 million Spire Healthcare hospital, a new 80-bedroom healthcare unit at West London Mental Health Centre, a £8.1m expansion of a groundbreaking neuroscience hospital at The Walton Centre and recently the installation of 10 all-new antimicrobial BioPod units at Harrogate Hospital Accident and Emergency department.
BioClad’s cutting-edge products are now in high demand across the globe and the company’s international trade has expanded rapidly in India, Saudi Arabia, Canada, Australia, New Zealand, Pakistan, United Arab Emirates and Egypt.
BioClad Director Lindsay McKenzie will attend The Queen’s Reception at Buckingham Palace. The Queen’s Award will be presented to the company at their UK head office in Harrogate by the county’s Lord-Lieutenant.